Published in Blood on May 01, 1998
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging (2003) 1.34
(18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging (2010) 1.30
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol (2009) 1.24
PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2003) 1.09
Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging (2006) 1.07
Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging (2009) 1.07
Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.06
Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2006) 1.02
Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging (2005) 1.00
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer (2004) 0.90
Clinical utility of ¹⁸F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma. Br J Radiol (2012) 0.89
Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur J Nucl Med Mol Imaging (2003) 0.89
PET and PET/CT imaging of skeletal metastases. Cancer Imaging (2010) 0.88
Usefulness of (18)F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma. Nucl Med Mol Imaging (2012) 0.85
The role of SPET and PET in monitoring tumour response to therapy. Eur J Nucl Med Mol Imaging (2003) 0.84
Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil. Clinics (Sao Paulo) (2009) 0.81
State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". Front Oncol (2013) 0.81
Increased bone marrow uptake of 18F-FDG in leukemia patients: preliminary findings. Springerplus (2015) 0.80
Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT. Medicine (Baltimore) (2014) 0.79
PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. Curr Hematol Malig Rep (2016) 0.78
PET in lymphoma. Cancer Imaging (2006) 0.77
The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma. Cancer Res Treat (2014) 0.77
Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging (2006) 0.76
Cervical lymphadenopathy: Unwinding the hidden truth. Dent Res J (Isfahan) (2017) 0.75
25 Years Old Women With Inflammatory Low Back Pain. Med Arch (2016) 0.75
Non-Specific Disease Mimicking Malignancy: Two Cases of FDG Uptake in the Extremities. Nucl Med Mol Imaging (2010) 0.75
Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma? Turk J Haematol (2015) 0.75
Three cases of fever of unknown origin (FUO) with acute multifocal non-bacterial osteitis (NBO) as reactive osteomyelitis. Rheumatol Int (2011) 0.75
Endoscopic evaluation of gastrointestinal lesions noted incidentally on PET scanning. Dig Dis Sci (2005) 0.75
Burnout and psychiatric disorder among cancer clinicians. Br J Cancer (1995) 4.47
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet (1995) 2.74
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol (2005) 2.65
Comparison of technetium-99m-HM-PAO leukocytes with indium-111-oxine leukocytes for localizing intraabdominal sepsis. J Nucl Med (1990) 2.63
Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med (1996) 2.03
Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. Eur J Nucl Med (1999) 1.95
PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med (1997) 1.83
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med (1990) 1.81
Appropriate chemotherapy for palliating advanced cancer. BMJ (1992) 1.80
A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med (1999) 1.67
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol (2005) 1.66
A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant (2006) 1.66
99Tcm sestamibi--a new agent for parathyroid imaging. Nucl Med Commun (1989) 1.63
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2000) 1.62
Strongyloides stercoralis hyperinfection associated with cimetidine in an immunosuppressed patient: diagnosis by endoscopic biopsy. Gut (1986) 1.59
Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging (2003) 1.59
Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. Eur Respir J (1991) 1.54
The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma. Eur J Surg Oncol (2006) 1.51
Focal abnormalities detected by 18FDG PET in epileptic encephalopathies. Arch Dis Child (1996) 1.48
18F-FDG PET-CT uptake is a feature of both normal diameter and aneurysmal aortic wall and is not related to aneurysm size. Eur J Nucl Med Mol Imaging (2014) 1.47
Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer (2012) 1.41
Gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant (1994) 1.40
Secretion of [123I] iodide in breast milk following administration of [123I] meta-iodobenzylguanidine. Eur J Nucl Med (1994) 1.39
Is perfusion lung scanning hazardous in pulmonary hypertension? Nucl Med Commun (1995) 1.38
Cerebral perfusion deficits in divers with neurological decompression illness. Nucl Med Commun (1993) 1.38
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia (2011) 1.36
18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma (2000) 1.34
Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol (1998) 1.27
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg (1999) 1.24
Chemical composition of nucleosomes among domains of calf thymus chromatin differing in micrococcal nuclease accessibility and solubility properties. J Biol Chem (1981) 1.22
Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer (2000) 1.16
Histone modifications in the yeast S. Cerevisiae. Nucleic Acids Res (1981) 1.15
Radionuclide parathyroid imaging. J Nucl Med (1997) 1.15
The surgical treatment of metastatic disease of the spine. Radiother Oncol (2000) 1.14
Dual energy X-ray absorptiometry normal reference range use within the UK and the effect of different normal ranges on the assessment of bone density. Br J Radiol (1995) 1.13
Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br (1998) 1.12
A new method for the preparation of minicells for physiological studies. Prep Biochem (1973) 1.11
Fluctuation in polyadenylate size and content in exponential- and stationary-phase cells of Saccharomyces cerevisiae. J Bacteriol (1980) 1.11
Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study. J Clin Pathol (2009) 1.10
Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia? J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.10
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol (2010) 1.08
Letter to the editor re: positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol (2013) 1.07
Radiation dose rates post 131I therapy and advice to patients on discharge from hospital. Health Phys (1997) 1.07
The value of the chest radiograph in reporting aerosol ventilation-perfusion scans. Nucl Med Commun (1998) 1.07
Radiation dose rates from patients undergoing PET: implications for technologists and waiting areas. Eur J Nucl Med (2000) 1.07
Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation. Am Rev Respir Dis (1993) 1.06
(99m)Tc(V)DMSA quantitatively predicts (188)Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med (2000) 1.06
18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol (2000) 1.02
Radiotherapy in the treatment of Hodgkin's disease. Br Med J (1978) 1.01
FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging (2002) 1.00
Recent advances in refractory coeliac disease: a review. Histopathology (2009) 1.00
Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers. Thorax (1991) 0.99
What's the price of a research subject? N Engl J Med (1999) 0.99
The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging (2004) 0.99
A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Neurology (1997) 0.98
Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med (1996) 0.97
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J (2011) 0.97
Regional lung epithelial leakiness in smokers and nonsmokers. Nucl Med Commun (1985) 0.96
Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet (1984) 0.94
Osteonecrosis in Hodgkin's disease. Br J Radiol (1978) 0.93
Gliomatosis cerebri: disconnection of the cortical grey matter, demonstrated on PET scan. Br J Neurosurg (1998) 0.93
Rapid isolation of yeast nuclei. Curr Genet (1981) 0.92
Pulmonary deposition of a nebulised aerosol during mechanical ventilation. Thorax (1993) 0.92
Low dose fractionated whole body irradiation in the treatment of advanced non-Hodgkin's lymphoma. Cancer (1979) 0.92
Variability in the measurement of nebulized aerosol deposition in man. Clin Sci (Lond) (1991) 0.92
Recurrent Strongyloides stercoralis infection in a patient with T-cell lymphoma-leukaemia. Lancet (1984) 0.92
[(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg (2000) 0.91
Lung 99Tcm-DTPA transfer: a method for background correction. Nucl Med Commun (1985) 0.91
Non-invasive management of fever and breathlessness in HIV positive patients. Eur Respir J (1991) 0.91
Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med (2000) 0.90
Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med (2001) 0.90
The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol (2000) 0.89
Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med (2000) 0.89
Influence of scalp hypothermia on doxorubicin related alopecia. Lancet (1980) 0.89
Computer planning of stereotactic iodine-125 seed brachytherapy for recurrent malignant gliomas. Br J Radiol (1995) 0.89
FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med (2001) 0.88
2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol (2000) 0.88
Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg (1999) 0.87
18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol (Oxf) (2006) 0.87
Positron emission tomography in imaging spinal cord tumors. J Child Neurol (2000) 0.87
Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily. Rev Infect Dis (1990) 0.87
Ventilation perfusion imaging--again. Nucl Med Commun (1992) 0.86
Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. Radiother Oncol (1997) 0.86
Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma. Eur J Nucl Med (1998) 0.86
Solid phase synthesis of [18F]labelled peptides for positron emission tomography. Bioorg Med Chem Lett (2000) 0.85
Folic acid absorption in patients infected with the human immunodeficiency virus. J Intern Med (1991) 0.85
The challenges of integrating molecular imaging into the optimization of cancer therapy. Integr Biol (Camb) (2011) 0.85
Positron emission tomography in the management of lymphomas. Clin Oncol (R Coll Radiol) (2002) 0.85
Allelic association of sequence variants in the herpes virus entry mediator-B gene (PVRL2) with the severity of multiple sclerosis. Genes Immun (2006) 0.84